JAMA Neurology : Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease
Interview with Charbel Moussa, MD, PhD, author of Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
Source: JAMA Specialty Journals Author Interviews - Category: General Medicine Source Type: podcasts
More News: Brain | Clinical Trials | General Medicine | Neurology | Nilotinib | Parkinson's Disease | Tasigna